

FOR IMMEDIATE RELEASE  
Kevin Nickels  
President and CEO  
Celleration, Inc.  
10250 Valley View Road  
Suite 137  
Eden Prairie, MN 55344  
(952) 224-8700  
www.celleration.com



**Celleration, Inc. announces the national launch of the MIST Therapy™ System 5.0 Wound Treatment Device**

The MIST Therapy System 5.0 is a wound care product designed to impact key areas of the wound repair process. Mist Therapy produces a low intensity ultrasound generated mist; Mist Therapy is intended for the cleansing and maintenance debridement of wounds including the removal of fibrin, yellow slough, wound exudates and bacteria all of which are paramount to the healing process. This indication allows Celleration's proprietary non-contact MIST Technology™ to be used on a variety of wounds including, but not limited to, acute, traumatic, chronic and dehisced wounds.



The MIST Therapy System 5.0 is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (non-contact). The system generates and propels the therapeutic mist towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon drives them toward the wound. Treatments take only minutes and improved clinical outcomes can often be seen within just a few treatments.

The MIST Therapy System 5.0 consists of an ultrasonic power supply (generator), a transducer (handset), and a single use applicator that holds a pre-packaged saline bottle. The generator is compact, lightweight, portable and adaptable to standard power sources.

The MIST Therapy System 5.0 consists of

This product has cleared by the FDA for sale in the United States.

**About the Company:**

Celleration, Inc. a privately held medical device company was founded in 1999, to develop and commercialize its therapeutic ultrasound platform. The patented MIST Technology utilizes low intensity ultrasonic sound waves to produce an energized mist of sterile saline in a non-contact fashion. Critical to the Company's strategy is ongoing clinical and scientific research to provide evidence supporting the efficacy of this new technology. The Company's initial focus has been the chronic diabetic foot ulcer market and it has recently completed a prospective, randomized, double-masked, sham controlled multi-center study in diabetic foot ulcers to pursue additional indications for the MIST Technology.



For more information on Celleration, Inc. and the MIST Therapy System 5.0 contact Mr. Chris Ernster, VP of Sales and Marketing 952-224-8700.

